🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

455 results for “60” Clear

  1. Placebo (inhalation powder capsules) containing 1 of 4 dosage strengths of TPIP (80 μg, 160 μg, or 320 μg or 640 µg ), TREPROSTINIL PALMITIL INHALATION POWDER, TREPROSTINIL PALMITIL INHALATION POWDER, TREPROSTINIL PALMITIL INHALATION POWDER, TREPROSTINIL PALMITIL INHALATION POWDER

    Insmed Limited

    Pulmonary Hypertension Associated with Interstitial Lung Disease

    phase 3 small molecule active

    1 trial

  2. Placebo (ziltivekimab), ziltivekimab

    Novo Nordisk A/S

    Atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation

    phase 3 small molecule active

    1 trial

  3. Placebo (ziltivekimab), ziltivekimab

    Novo Nordisk A/S

    Acute myocardial infarction

    phase 3 small molecule active

    1 trial

  4. Placebo for AMG 334, Erenumab

    Amgen Technology (Ireland) UC

    Chronic Migraine

    phase 3 small molecule active

    1 trial

  5. Placebo for AZP-3601 Pen A and Pen B, AZP-3601, CALCIUM ARROW 500 mg, comprimé à sucer, AZP-3601, UN-ALFA 0,50 microgramme, capsule molle, ROCALTROL 0,25 microgramme, capsule molle

    Alexion Europe SAS

    Hypoparathyroidism

    phase 3 small molecule active

    1 trial

  6. Placebo for Benralizumab, Fasenra 30 mg solution for injection in pre-filled syringe, Symbicort forte Turbuhaler 320 microgramos/9 microgramos/inhalación polvo para inhalación., Symbicort Turbuhaler 160 microgramos/4,5 microgramos/inhalación polvo para inhalación

    AstraZeneca AB

    Eosinophilic Asthma

    phase 3 small molecule active

    1 trial

  7. Placebo for PF-06651600-15, 50 mg, DEXAMETHASONE, Ritlecitinib tosilate, Placebo for PF-06651600-15, 100 mg, Ritlecitinib Tosilate

    Pfizer Ireland Pharmaceuticals Unlimited Company

    nonsegmental vitiligo

    phase 3 small molecule active

    1 trial

  8. Placebo of Procoralan 5 mg, Procoralan 5 mg film-coated tablets

    Pari Pharma GmbH

    Septic shock

    phase 3 small molecule active

    1 trial

  9. Placebo pMDI to match budesonide/formoterol fumarate pMDI, PREDNISOLONE, Placebo MDI to match to Budesonide, Glycopyronium and Formoterol Fumarate/ Budesonide and Formoterol Fumarate MDI, SALBUTAMOL, Trixeo Aerosphere 5 micrograms/7.2 micrograms/160 micrograms pressurised inhalation, suspension, Budesonide, Glycopyronium and Formoterol Fumarate, Symbicort, 160 mikrogram/4,5 mikrogram/puff inhalationsspray, suspension

    AstraZeneca AB

    Severe and inadequately controlled asthma

    phase 3 small molecule active

    1 trial

  10. Placebo to Clostridium Botulinum neurotoxin type A (150 kD), CLOSTRIDIUM BOTULINUM NEUROTOXIN TYPE A (150KD), FREE OF COMPLEXING PROTEINS

    Merz Therapeutics GmbH

    Chronic migraine

    phase 3 small molecule active

    1 trial

  11. Placebo to Ponsegromab (PF-06946860), CALCIUM LEVOFOLINATE PENTAHYDRATE, Ponsegromab (PF-06946860)

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Cancer cachexia

    phase 3 small molecule active

    1 trial

  12. Pravafenix 40 mg/160 mg hard capsules

    Laboratoire HRA Pharma

    Dyslipidaemia

    phase 3 small molecule active

    1 trial

  13. Prolia 60 mg solution for injection in pre-filled syringe, LY06006

    Ology Bioservices Ireland LTD

    Postmenopausal osteoporosis

    phase 3 small molecule active

    1 trial

  14. RBP-6000

    Indivior Europe Limited

    Opioid Use Disorder

    phase 3 small molecule completed

    4 trials

  15. RLY-2608

    Relay Therapeutics

    PIK3CA Mutation

    phase 3 small molecule active

    2 trials

  16. RO7046015, Placebo Prasinezumab

    Roche Registration Limited

    Early-Stage Parkinson’s Disease (PD)

    phase 3 small molecule active

    1 trial

  17. RO7046015, RO7046015, RO7046015 Placebo

    Roche Registration Limited

    Early Parkinson's disease

    phase 3 small molecule active

    1 trial

  18. Reblozyl 75 mg powder for solution for injection, Reblozyl 25 mg powder for solution for injection

    Celgene Europe Limited

    Myelodysplastic syndrome

    phase 3 small molecule active

    1 trial

  19. Revatio 0.8 mg/ml solution for injection

    Pari Pharma GmbH

    Hypoxic ischemic encephalopathy

    phase 3 small molecule active

    1 trial

  20. Revlimid 2.5 mg hard capsules, Revlimid 5 mg hard capsules, Revlimid 15 mg hard capsules, Revlimid 20 mg hard capsules, Revlimid 10 mg hard capsules, Revlimid 25 mg hard capsules, SOLDESAM 0,2% gocce orali, soluzione, Kyprolis 60 mg powder for solution for infusion

    Fondazione Telethon ETS

    PATIENTS WITH NEW DIAGNOSIS MULTIPLE MYELOMA WITH AGE >= 65 YEARS OR NOT ELIGIBLE TO ASCT

    phase 3 small molecule active

    1 trial

  21. Roflumilast (Daliresp®) 500µg, Roflumilast (Daliresp®) 250µg, CHF6001 DPI, Placebo to match CHF6001 DPI, CHF6001 DPI, Placebo to match Roflumilast (Daliresp®)

    Chiesi Farmaceutici S.p.A

    Chronic Obstructive Pulmonary Disease (COPD)

    phase 3 small molecule active

    1 trial

  22. Rukobia 600 mg prolonged-release tablets

    ViiV Healthcare BV

    Heavily Treatment Experienced Subjects Infected with Multi-drug Resistant (MDR) HIV-1

    phase 3 small molecule active

    1 trial

  23. Rusfertide 45mg, Rusfertide 60mg, Rusfertide 30mg, Rusfertide 10mg, Rusfertide 20mg, Placebo to Match PTG-300 for Injection. Formulation (lyophilized powder) is based upon that of PTG-300 for Injection, with the drug substance omitted.

    Protagonist Therapeutics, Inc

    Polycythemia Vera

    phase 3 small molecule active

    1 trial

  24. SAMYR 400 mg compresse gastroresistenti, Samyr placebo (same excipient as SAMYR)

    Mylan dura GmbH

    Major Depression Disorder

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources